Bentsur Ron's Form 4 filing
Nuvectis Pharma, Inc. (NVCT) · filed Jul 18, 2023
- Accession no.
- 0001104659-23-081834
- Filed
- Jul 18, 2023
- Trade date
- Jul 7-14, 2023
- Filing delay
- 11 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $4.04K. It was filed 11 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bentsur RonCIK 0001251213 | Director, Officer (Chairman & CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2023 | Common Stock | PPurchaseAcquired | +110 | $16.19 | +$1,780.9 | 3,231,209 | Direct | |
| Jul 14, 2023 | Common Stock | PPurchaseAcquired | +150 | $15.03 | +$2,254.5 | 3,231,359 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.